Our results indicate that IL-23R signaling in colon tumors is active in non-epithelial cells, likely infiltrating immune cells, but the causal effects of Treg cell-specific IL-23R signaling requires additional studies in humans to understand the implications in CRC pathogenesis. The gene discussed is IL23R; the disease is colorectal carcinoma.